AAWH
Ascend Wellness Holdings, Inc.Price & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $26.3M | Q1 2026 | — |
|
|
|||
| Adjusted EBITDA Margin non-GAAP | 22.5% | Q1 2026 | — |
|
|
|||
| Adjusted Gross Profit Margin non-GAAP | 46.1% | Q1 2026 | — |
| Ascenders Club loyalty sign-ups sequential increase | 34% | Q1 2026 | — |
| High Wired market share in infused flower category | 44% | Q1 2026 | — |
| Owned and partner owned and operated footprint | 51 | Q1 2026 | — |
| Percentage of sales at Ascend stores tied to loyalty members | 89% | Q1 2026 | — |
| Ascenders Club loyalty program active members growth | 23.7% | Q4 2025 | — |
| Ascenders Club loyalty program total membership growth | 56% | Q4 2025 | — |
| Loyalty members share of retail transactions | 88% | Q4 2025 | — |
| Retail footprint | 48 | Q4 2025 | — |
| Shares repurchased and retired | 15.8M | FY 2025 | — |
| SKUs developed and launched | 566 | FY 2025 | — |
| Retail stores | 47 | Q4 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AAWH
this stock
Ascend Wellness Holdings, Inc.
|
$86.87M | -41.0% | -10.9% | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$52.88B | +6.2% | — | — | 0.2% |
|
GALDY
Galderma Group AG/ADR
|
$50.15B | +3.2% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$42.98B | -3.5% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.0%
- Net QoQ
- 0 sh
- Top holder
- Millstreet Capital Manage…
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AAWH | -9.1% | -20.7% | -38.9% | -14.4% | -41.0% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -10.5% | -24.8% | -47.9% | -15.5% | -51.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.